H.C. Wainwright has initiated bullish coverage of four healthcare stocks headed into the end of 2017. Analyst Edward White explained his positive take on the four stocks in a research note on Thursday. Here’s a rundown of what he had to say.
Acceleron Pharma – Buy
White said the future of Acceleron Pharma Inc XLRN 0.14% lies in its leading drug candidate, Iuspatercept. Acceleron is currently co-developing the drug with Celgene Corporation CELG 0.12%. H.C. Wainwright is projecting peak sales of $2 billion for Iuspatercept, or roughly $400 million for Acceleron.
“We think luspatercept could be brought to the market by late 2019, and it will achieve blockbuster sales by 2026,” White wrote. H.C. Wainwright has a $57 price target for Acceleron stock.
Fate Therapeutics – Buy
White said Fate Therapeutics Inc FATE 0.45% has a strong pipeline of best-in-class drug candidates to treat cancer patients and other diseases with major unmet needs. According to White, the company’s leading candidate, ProTmune, has the highest probability of success, but that its NK-100 candidate has the highest upside.
“We project revenues of $329M and $68M for ProTmune and NK-100, respectively, in 2026,” White wrote. H.C. Wainwright has a $7 price target for Fate stock.
Mirati Therapeutics – Buy
White said Mirati Therapeutics, Inc. MRTX 7.5%’s precision oncology strategy will be a winner for long-term investors. Mirati is developing drugs that target specific mutations that are known to cause cancer. The stock recently jumped following positive data presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.
“We note Mirati’s products are in early development and project revenues of $210M, $175M, and $140M for glesatinib, sitravatinib, and mocetinostat, respectively, in 2026,” White wrote. H.C. Wainwright has a $20 price target for Mirati stock.
TESARO – Buy
White said TESARO Inc TSRO 0.09% isn’t getting enough credit for its U.S. Zejula launch and the rest of its impressive pipeline. He expects 2018 global revenue of $111 million from Varubi and $379 million from Zejula in 2018.
“We believe the stock’s current trading price serves…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
